Needham Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

Benzinga Newsdesk www.benzinga.com Positive 85.1%

Neg 0% Neu 0% Pos 85.1%

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $26 to $34.